Stuart A. Arbuckle - May 17, 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Comm & Ops Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
May 17, 2021
Transactions value $
-$23,589
Form type
4
Date filed
5/19/2021, 04:04 PM
Next filing
Jun 11, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$1.51K -7 -0.02% $215.33 41.2K May 17, 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$18.6K -86 -0.21% $216.36 41.1K May 17, 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale -$3.47K -16 -0.04% $217.15 41.1K May 17, 2021 Direct F1, F3, F5
holding VRTX Common Stock 140 May 17, 2021 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $215.33 (range $214.82 to $215.80).
F3 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $216.36 (range $215.82 to $216.76).
F5 Open market sales reported on this line occurred at a weighted average price of $217.15 (range $216.83 to $217.32).